Gyre Therapeutics, Inc. Interest Income (Expense), Net
Gyre Therapeutics, Inc. (GYRE) reported Interest Income (Expense), Net of $740.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2026-08-07
- Gyre Therapeutics, Inc. interest income (expense), net for the quarter ending 2026-06-30 was $740.00K, a 21.36% decline year-over-year.
- Gyre Therapeutics, Inc. interest income (expense), net for the quarter ending 2025-06-30 was $941.00K, a 168.86% increase year-over-year.
- Gyre Therapeutics, Inc. interest income (expense), net for the quarter ending 2024-12-31 was $346.00K, a 6.13% increase year-over-year.
- Gyre Therapeutics, Inc. interest income (expense), net for the quarter ending 2024-09-30 was $523.00K, a 84.81% increase year-over-year.
- Gyre Therapeutics, Inc. interest income (expense), net for fiscal 2025 was $1.75M, a 12.93% increase from fiscal 2024.
- Gyre Therapeutics, Inc. interest income (expense), net for fiscal 2024 was $1.55M, a 48.18% increase from fiscal 2023.
- Gyre Therapeutics, Inc. interest income (expense), net for fiscal 2023 was $1.04M, a 43.80% increase from fiscal 2022.
- Gyre Therapeutics, Inc. interest income (expense), net for fiscal 2022 was $726.00K.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $740.00K 10-Q · filed 2026-08-07 | $1.48M 10-Q · filed 2026-08-07 | ||
| 2025-12-31 | $1.75M 10-K · filed 2026-03-13 | |||
| 2025-06-30 | $941.00K 10-Q · filed 2026-08-07 | $1.80M 10-Q · filed 2026-08-07 | ||
| 2024-12-31 | $346.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $869.00K derived: sum of 2 quarters · filed 2026-03-13 | $1.22M derived: sum of 3 quarters · filed 2026-03-13 | $1.55M 10-K · filed 2026-03-13 |
| 2024-09-30 | $523.00K 10-Q · filed 2024-11-13 | $873.00K derived: sum of 2 quarters · filed 2024-11-13 | $1.20M 10-Q · filed 2024-11-13 | $1.53M derived: sum of 4 quarters · filed 2025-03-17 |
| 2024-06-30 | $350.00K 10-Q · filed 2024-08-13 | $678.00K 10-Q · filed 2024-08-13 | $1.00M derived: sum of 3 quarters · filed 2025-03-17 | $1.29M derived: sum of 4 quarters · filed 2025-03-17 |
| 2024-03-31 | $328.00K 10-Q · filed 2024-05-13 | $654.00K derived: sum of 2 quarters · filed 2025-03-17 | $937.00K derived: sum of 3 quarters · filed 2025-03-17 | $1.19M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-12-31 | $326.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $609.00K derived: sum of 2 quarters · filed 2025-03-17 | $860.00K derived: sum of 3 quarters · filed 2025-03-17 | $1.04M 10-K · filed 2025-03-17 |
| 2023-09-30 | $283.00K 10-Q · filed 2024-11-13 | $534.00K derived: sum of 2 quarters · filed 2024-11-13 | $718.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $251.00K 10-Q · filed 2024-08-13 | $435.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $184.00K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $726.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |